The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

Samuel D. Vasikaran, Paul Chubb

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    © 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of
    Original languageEnglish
    Pages (from-to)222-225
    Number of pages4
    JournalEndocrine
    Volume52
    Issue number2
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Bone Remodeling
    Osteoporosis
    Biomarkers
    Physiologic Monitoring
    Pathology
    Bone and Bones

    Cite this

    @article{a0296321ca524988ae796249c5d6f7e2,
    title = "The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis",
    abstract = "{\circledC} 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of",
    author = "Vasikaran, {Samuel D.} and Paul Chubb",
    year = "2016",
    doi = "10.1007/s12020-016-0900-2",
    language = "English",
    volume = "52",
    pages = "222--225",
    journal = "Endocrine",
    issn = "1355-008X",
    number = "2",

    }

    The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. / Vasikaran, Samuel D.; Chubb, Paul.

    In: Endocrine, Vol. 52, No. 2, 2016, p. 222-225.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

    AU - Vasikaran, Samuel D.

    AU - Chubb, Paul

    PY - 2016

    Y1 - 2016

    N2 - © 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of

    AB - © 2016, Springer Science+Business Media New York. The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of

    U2 - 10.1007/s12020-016-0900-2

    DO - 10.1007/s12020-016-0900-2

    M3 - Article

    VL - 52

    SP - 222

    EP - 225

    JO - Endocrine

    JF - Endocrine

    SN - 1355-008X

    IS - 2

    ER -